Studies Conducted at Department of Pharmaceuticals on Transdermal Delivery Recently Reported (Ex vivo and in vivo evaluation of microemulsion based transdermal delivery of E-coli specific T4 bacteriophage: A rationale approach to treat ...)
By a News Reporter-Staff News Editor at Biotech Week Current study results on Drugs and Therapies - Transdermal Delivery have been published. According to news reporting from Moradabad, India, by NewsRx journalists, research stated, "This study is focused on the development and evaluation of transdermal delivery of E. coli-specific T4 bacteriophages both ex-vivo and in-vivo using microemulsion as delivery carrier in eradicating the infection caused by E. coli. Microemulsions were prepared by mixing selected oil, surfactants and aqueous phase containing bacteriophages."
The news correspondents obtained a quote from the research from the Department of Pharmaceuticals, "The formulations were subjected to physicochemical characterization, ex-vivo and in-vivo permeation, stability studies, histological and immunofluorescence examination. The colloidal system exhibits a uniform size distribution, of finite size (150-320 nm). Transmission electron microscopy revealed the encapsulation of bacteriophage in the aqueous globule. Ex-vivo permeation across skin was successfully achieved as 6x 10(6) PFU/mL and 6.7 x10(6) PFU/mL of T4 permeated from ME 6% and 10%, respectively. ME 6% was found to be thermodynamically stable and in-vivo permeation resulted in 5.49x10(5) PFU/mL of bacteriophages in the blood of the E. coli challenged rats, while 2.48 x10(5) PFU/mL was detected in germ free rats, at the end of the study. Infected rats that were treated with bacteriophage were survived while significant mortality was observed in others. Histological and IL-6 immunofluorescence examination of the tissues revealed the efficacy/safety of the therapy."
According to the news reporters, the research concluded: "The microemulsion-based transdermal delivery of bacteriophage could be a promising approach to treat the infections caused by antibiotic-resistant bacteria."
For more information on this research see: Ex vivo and in vivo evaluation of microemulsion based transdermal delivery of E-coli specific T4 bacteriophage: A rationale approach to treat bacterial infection. European Journal of Pharmaceutical Sciences, 2017;107():168-182. European Journal of Pharmaceutical Sciences can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; European Journal of Pharmaceutical Sciences - www.journals.elsevier.com/european-journal-of-pharmaceutical-sciences/)
Our news journalists report that additional information may be obtained by contacting V. Rastogi, IFTM Univ, Dept. of Pharmaceut, Moradabad 244102, UP, India. Additional authors for this research include P. Yadav, A. Verma and J.K. Pandit (see also Drugs and Therapies - Transdermal Delivery).
Keywords for this news article include: Moradabad, India, Asia, Bacterial Infections and Mycoses, Transdermal Delivery, Drugs and Therapies, Immunofluorescence, Bacteriophages, Biotechnology, Viruses, Department of Pharmaceuticals.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC